Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis
Authors' conclusion
TMZ was the most frequently reported therapy, with PR as the predominant outcome. However, the limited data on ICIs, PRRT, bevacizumab, lapatinib, and everolimus yielded imprecise results, highlighting the need for further research with the aim of gaining more insights into treatment effects of antineoplastic drug therapies for APTs and PCs.
Study context
- Population
- Patients with pituitary carcinoma (PC) or aggressive pituitary tumor (APT)78 studies
- Comparison
- Antineoplastic drug therapies for aggressive pituitary tumors (APTs) and pituitary carcinomas (PCs)
- Temozolomide (TMZ)n = 434
- Outcome
- Tumor control: frequencies of complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD)
Methodological detailsproportional meta-analyses, Searched MEDLINE, EMBASE, LILACS and CENTRAL; two independent reviewers selected studies, assessed risk of bias and extracted data
- Proportional meta-analyses
- Searched MEDLINE, EMBASE, LILACS and CENTRAL; two independent reviewers selected studies, assessed risk of bias and extracted data
Pooled result
As reported in the abstract
Tumor response (CR, PR, SD, PD)
| Group | Value | Complete response (CR) | Partial response (PR) | SD | Progressive disease (PD) |
|---|---|---|---|---|---|
| TMZ | PR 33% (95% CI 28–37) | 4% (95% CI, 1-13) | 33% (95% CI, 28-37) | 32% (95% CI, 28-36) | 29% (95% CI, 25-34) |
| Immune checkpoint inhibitors (ICIs) | PR 24% (95% CI 11–44) | 24% (95% CI, 11-44) | 12% (95% CI, 4-31) | 67% (95% CI, 24-93) |
Value
TMZPR 33% (95% CI 28–37)
Immune checkpoint inhibitors (ICIs)PR 24% (95% CI 11–44)
Complete response (CR)
TMZ4% (95% CI, 1-13)
Immune checkpoint inhibitors (ICIs)— not stated in the abstract
Partial response (PR)
TMZ33% (95% CI, 28-37)
Immune checkpoint inhibitors (ICIs)24% (95% CI, 11-44)
SD
TMZ32% (95% CI, 28-36)
Immune checkpoint inhibitors (ICIs)12% (95% CI, 4-31)
Progressive disease (PD)
TMZ29% (95% CI, 25-34)
Immune checkpoint inhibitors (ICIs)67% (95% CI, 24-93)
Original publication
Effect of antineoplastic drug therapies on carcinoma and aggressive pituitary tumors: a systematic review and meta-analysis. Pituitary. Published 2 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →